Insilico and Lilly Reset the Price of AI Drug Discovery. Oncology AI Enters the Clinical Standard.
Last week, the compute got installed. This week, the deals got signed. Insilico Medicine closed a $2.75 billion collaboration with Eli Lilly — $115 million upfront, exclusive worldwide license, multiple therapeutic areas — the largest capital commitment to an external AI drug discovery platform from a top-5 pharma to date. Caris Life Sciences launched an AI tool that guides first-line therapy selection for pancreatic cancer at the molecular level. The tool runs on tissue already collected for standard molecular profiling — no additional biopsy required. Tempus AI moved from data vendor to embedded development partner inside a Daiichi Sankyo drug program. And Merck confirmed 34,000 monthly users on its internal AI, with autonomous agents cutting commercial insight generation time in half. The question was never whether AI would reshape drug discovery. The question was who would pay for it, at what scale, and when. This week, Lilly answered all three.
